Celldex

Bispecific antibodies
#Bispecific Antibodies #Celldex #Fibrosis #Monoclonal antibodies #Phase I trial

CDX-622 demonstrates sustained mast cell inhibition

Celldex has revealed positive data from the ongoing Phase I study of CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis.  These pathways are mast cell depletion via stem cell factor (SCF) starvation and neutralisation of the alarmin thymic stromal… Read More

#News